Longeveron (LGVN) Other Non Operating Income (2020 - 2026)
Longeveron (LGVN) posted quarterly Other Non Operating Income of $39000.0 for Q1 2026, down 77.06% year-over-year from $170000.0 in Q1 2025, and down 25.0% quarter-over-quarter from $52000.0 in Q4 2025.
Longeveron (LGVN) Other Non Operating Income (2020 - 2026) Analysis & Trends
Longeveron's Other Non Operating Income history runs 7 years deep, the most recent figure standing at $39000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income fell 77.06% year-over-year to $39000.0; the TTM figure through Mar 2026 stood at $549000.0 (down 20.09% YoY), while the FY2025 annual figure was $680000.0, up 23.86% from the prior year.
- Other Non Operating Income for Q1 2026 stood at $39000.0, down from $52000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $1.9 million in Q4 2022, with the low at -$1.4 million in Q2 2022.
- The 5-year median for Other Non Operating Income is $69000.0 (2023), against an average of $70058.8.
- Peak annual rise in Other Non Operating Income reached 5170.27% in 2022, while the deepest fall reached 2798.08% in 2022.
- Longeveron's Other Non Operating Income stood at $1.9 million in 2022, then sank by 130.97% to -$581000.0 in 2023, then jumped by 134.42% to $200000.0 in 2024, then sank by 74.0% to $52000.0 in 2025, then retreated by 25.0% to $39000.0 in 2026.
- Business Quant data shows LGVN's Other Non Operating Income at $39000.0 in Q1 2026, $52000.0 in Q4 2025, and $89000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98,000.00 |
| Mar 31, 2026 | 39,000.00 |
| Dec 31, 2025 | 52,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 369,000.00 |
| Mar 31, 2025 | 170,000.00 |
| Dec 31, 2024 | 200,000.00 |
| Sep 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | 32,000.00 |
| Dec 31, 2023 | -581,000.00 |
| Sep 30, 2023 | 55,000.00 |
| Jun 30, 2023 | 80,000.00 |
| Mar 31, 2023 | 69,000.00 |
| Dec 31, 2022 | 1.88 Mn |
| Sep 30, 2022 | -57,000.00 |
| Jun 30, 2022 | -1.40 Mn |
| Mar 31, 2022 | -116,000.00 |
| Dec 31, 2021 | -37,000.00 |
| Sep 30, 2021 | 50,000.00 |